Trial Profile
A clinical trial to evaluate the pharmacokinetics and safety of idelalisib in healthy volunteers and in subjects with moderate or severe hepatic impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 09 Nov 2015 New trial record